Turpaz Industries (TRPZ) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
3 Nov, 2026Executive summary
Record Q3 revenue rose 50.1% YoY to $48.7M; adjusted EBITDA increased 59.3% to $12.0M, with margin at 24.7%.
9M revenue reached a record $134.5M, up 43.1%; adjusted EBITDA rose 50.3% to $30.3M, with margin at 22.6%.
Growth reflected acquisitions and organic expansion in Taste and Scent; sales outside Israel and the Middle East represented ~85% of total sales.
Financial highlights
Q3 gross profit rose 53.6% to $19.9M; gross margin improved to 40.9% from 40.0%.
Q3 operating profit rose to $7.7M from $5.2M, while operating margin was 15.8% versus 16.0%; net profit increased to $4.6M from $4.0M.
9M gross profit rose 45.6% to $52.4M; gross margin was 39.0% versus 38.3%. Operating profit increased to $19.1M from $13.1M, and net profit to $11.4M from $9.5M.
9M basic and diluted EPS was $0.10 versus $0.09; finance expenses rose to $4.0M from $1.7M, mainly due to borrowing costs and non-cash put-option expenses.
9M cash flow from operations was $15.7M versus $6.6M; Q3 operating cash flow was $4.4M versus $6.4M.
Outlook and guidance
Portfolio expansion in citrus products and aroma chemicals is expected to support Specialty Fine Ingredients’ return to growth by 2025; plans remain subject to market and execution risks.
Strategy targets double-digit growth through acquisitions and organic expansion, with synergies from cross-selling, procurement, R&D, marketing and regulatory functions.
Liquidity, operating cash flow and financing access are expected to support continued operations and the combined growth strategy; acquisition pipeline remains strong.
Latest events from Turpaz Industries
- Record Q1 growth was led by Taste and acquisitions, while Specialty Fine Ingredients weakened.TRPZ
Q1 2024 - Acquisitions and Taste/Scent growth lifted record results despite Specialty Fine Ingredients weakness.TRPZ
Q2 2024 - FY24 sales rose 48.4%, with adjusted EBITDA up 54.8%.TRPZ
Q4 2024 - Record Q1 sales of $60.4M and adjusted EBITDA of $13.6M reflected organic growth and acquisitions.TRPZ
Q1 2025 - Q2 sales grew 35.6%, with 14.2% organic growth and a 23.1% adjusted EBITDA margin.TRPZ
Q2 2025 - Q3 sales rose 57.4% as organic growth and acquisitions lifted adjusted EBITDA 55.1%.TRPZ
Q3 2025 - Revenue rose 45.6% in 2025 as adjusted EBITDA margin reached 23.1%.TRPZ
Q4 2025 - Q1 revenue rose 38.6%; Phoenix and Romessence lifted the sales run rate to $380m.TRPZ
Q1 2026 - Acquisitions and organic growth drove record sales, while integration and production ramp-up shape the outlook.TRPZ
Q2 2026